Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $6.1 million.

  • RxSight's Cost of Revenue fell 3943.93% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year decrease of 1218.26%. This contributed to the annual value of $41.0 million for FY2024, which is 1606.25% up from last year.
  • As of Q3 2025, RxSight's Cost of Revenue stood at $6.1 million, which was down 3943.93% from $8.4 million recorded in Q2 2025.
  • RxSight's 5-year Cost of Revenue high stood at $11.4 million for Q4 2024, and its period low was $2.4 million during Q1 2021.
  • Its 5-year average for Cost of Revenue is $7.7 million, with a median of $8.4 million in 2025.
  • In the last 5 years, RxSight's Cost of Revenue surged by 11906.98% in 2022 and then plummeted by 3943.93% in 2025.
  • Quarter analysis of 5 years shows RxSight's Cost of Revenue stood at $5.6 million in 2021, then surged by 55.95% to $8.7 million in 2022, then grew by 26.08% to $10.9 million in 2023, then increased by 4.58% to $11.4 million in 2024, then plummeted by 46.5% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $8.4 million for Q2 2025, and $9.6 million during Q1 2025.